Peptide Profile

Dulaglutide

Q: What is dulaglutide used for in research?

Dulaglutide (Trulicity) is an FDA-approved GLP-1 receptor agonist studied primarily for glycaemic control in type 2 diabetes, cardiovascular risk reduction (REWIND trial), weight management (AWARD-11 higher doses), and renal protection. The AWARD clinical programme spans 10+ Phase III trials covering these domains.

Q: How does dulaglutide differ from semaglutide?

Both are weekly injectable GLP-1 receptor agonists, but they use different half-life extension strategies: dulaglutide uses Fc fusion (IgG4 domain) while semaglutide uses fatty acid acylation for albumin binding. Semaglutide generally demonstrates greater weight loss efficacy, while dulaglutide offers a simpler single-use pen device requiring no reconstitution.

Q: What are the most common dulaglutide side effects?

The most frequently reported dulaglutide side effects are gastrointestinal: nausea (12–17%), diarrhoea (8–16%), and vomiting (5–14%). These are typically mild to moderate, dose-dependent, and tend to diminish during the first weeks of treatment. Trulicity side effects are consistent with the broader GLP-1 receptor agonist class.

Q: What did the REWIND trial demonstrate?

The REWIND trial (Gerstein 2019) showed that dulaglutide 1.5 mg reduced major adverse cardiovascular events (MACE) by 12% (HR 0.88) versus placebo over a median 5.4-year follow-up in 9,901 participants with type 2 diabetes. Notably, it enrolled a broader population than other GLP-1 RA cardiovascular trials, with lower baseline HbA1c and more women.

Q: How much weight loss does dulaglutide produce?

Weight loss with dulaglutide is moderate compared with newer GLP-1 receptor agonists. In AWARD-11, the highest studied dose (4.5 mg) produced approximately 4.7 kg weight loss at 36 weeks. This is less than semaglutide 2.4 mg (~15% body weight) or tirzepatide (~20–22.5%), positioning Trulicity weight loss as meaningful but not class-leading.

Q: What is the half-life of dulaglutide?

Dulaglutide has an approximate half-life of 5 days (~120 hours), achieved through its unique Fc fusion design that prevents renal clearance and engages FcRn-mediated recycling. This supports once-weekly dosing, with steady-state concentrations reached within 2–4 weeks.

Q: Is dulaglutide suitable for investigation in kidney disease?

Yes — unlike many antihyperglycaemic agents, dulaglutide is not predominantly cleared by the kidneys. The AWARD-7 trial (Tuttle 2018) specifically evaluated dulaglutide in CKD stages 3–4, demonstrating maintained glycaemic control with potentially slower eGFR decline compared with insulin glargine. The REWIND renal analysis also showed a 15% reduction in the composite renal endpoint.

Q: What doses of dulaglutide have been studied?

The approved doses are 0.75 mg and 1.5 mg administered once weekly. The AWARD-11 trial evaluated higher doses of 3.0 mg and 4.5 mg, demonstrating dose-dependent improvements in both glycaemic control and weight loss. As of the latest data, the 3.0 mg and 4.5 mg doses have received regulatory approval in some markets for additional glycaemic benefit.

Updated April 4, 2026

Appetite & Weight Management Fat Loss & Recomp Metabolic Health / Insulin Sensitivity

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Dulaglutide?

Dulaglutide is a long-acting GLP-1 receptor agonist developed by Eli Lilly and approved by the FDA in 2014 under the brand name Trulicity for use in type 2 diabetes management. Unlike other GLP-1 receptor agonists that achieve extended half-lives through albumin binding (as with semaglutide) or fatty acid acylation (as with liraglutide), dulaglutide uses a fundamentally different engineering approach: it fuses a modified GLP-1 analog to a human IgG4 Fc domain. This Fc fusion creates a large molecule that avoids renal clearance and resists DPP-4 enzymatic degradation, enabling once-weekly dosing from a single-use prefilled pen device — no reconstitution or mixing required.[1][2]

The compound (CAS: 923950-08-7) has been investigated across the full AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) clinical trial programme, comprising more than ten Phase III randomised controlled trials enrolling thousands of participants. Approved doses are 0.75 mg and 1.5 mg weekly, with higher doses of 3.0 mg and 4.5 mg subsequently evaluated in AWARD-11.[3]

Compound Profile

Peptide Name

Dulaglutide (Trulicity®)

Active Moiety

GLP-1 analog (90% homology to native GLP-1) fused to modified IgG4-Fc

CAS Number

923950-08-7

Molecular Formula

C₂₆₀₀H₄₀₁₆N₆₉₂O₇₉ₓS₁₆

Molecular Weight

~59,670 g/mol

Origin

Engineered GLP-1 analog fused to immunoglobulin Fc domain

Evidence Confidence

High — multiple Phase III trials (AWARD programme)

Mechanism of Action

The dulaglutide mechanism centres on selective agonism of the GLP-1 receptor, mimicking the activity of endogenous glucagon-like peptide-1. Understanding how dulaglutide works requires appreciating both its pharmacodynamic action and structural engineering.

The GLP-1 receptor agonism produces several interconnected effects:

Glucose-dependent insulin secretion: GLP-1 receptor activation on pancreatic beta cells enhances insulin release only when blood glucose is elevated, reducing the risk of hypoglycaemia compared with sulfonylureas or exogenous insulin.[1][4]
Glucagon suppression: dulaglutide suppresses inappropriate glucagon secretion from alpha cells in a glucose-dependent manner, further reducing hepatic glucose output.
Gastric emptying delay: slowed gastric motility prolongs post-meal satiety, contributing to reduced caloric intake.
Central appetite regulation: GLP-1 receptor activation in hypothalamic and brainstem regions reduces hunger signals and food cravings.

The Fc fusion design is what sets dulaglutide apart structurally. By covalently linking the GLP-1 analog to a modified IgG4 Fc domain via a peptide linker, the resulting fusion protein (~63 kDa) is too large for rapid renal filtration. The Fc domain also engages the neonatal Fc receptor (FcRn), which recycles the molecule back into circulation after cellular uptake — the same mechanism that gives natural IgG antibodies their extended half-life. This produces a pharmacokinetic profile supporting weekly administration, with steady-state plasma concentrations achieved within 2–4 weeks of repeated dosing.[1]

Glycaemic Control Research

The AWARD programme represents one of the most comprehensive Phase III clinical trial datasets for any GLP-1 receptor agonist. Across these trials, dulaglutide consistently demonstrated clinically significant reductions in HbA1c across diverse patient populations and comparators.

Key glycaemic findings from the AWARD programme include:

AWARD-1 (Wysham 2014): dulaglutide 1.5 mg reduced HbA1c by -1.51% at 26 weeks versus -0.99% for exenatide twice daily and -0.46% for placebo, when added to metformin and pioglitazone. Both dulaglutide doses demonstrated superiority over exenatide and placebo (p < 0.001).[1]
AWARD-4 (Blonde 2015): in patients requiring treatment intensification with prandial insulin lispro, dulaglutide 1.5 mg achieved HbA1c reductions of -1.64% compared with -1.41% for insulin glargine at 26 weeks, demonstrating non-inferiority and superiority.[5]
AWARD-5 (Nauck 2014): dulaglutide 1.5 mg produced HbA1c reductions of -1.10% at 52 weeks versus -0.39% for sitagliptin 100 mg (p < 0.001), with superiority maintained through 104 weeks of follow-up.[4][6]
AWARD-6 (Dungan 2014): in a head-to-head comparison with liraglutide 1.8 mg, dulaglutide 1.5 mg demonstrated non-inferior HbA1c reduction (-1.42% versus -1.36%, treatment difference -0.06%, 95% CI -0.19 to 0.07).[7]
AWARD-11 (Frias 2021): higher doses of 3.0 mg and 4.5 mg provided additional glycaemic benefit beyond the approved 1.5 mg dose, with dulaglutide 4.5 mg achieving superior HbA1c reductions (-1.77% versus -1.54% at 36 weeks, p < 0.001).[3]

A composite endpoint analysis across the AWARD programme (Dungan 2016) demonstrated that 37–58% of patients on dulaglutide 1.5 mg achieved the combined target of HbA1c <7.0%, no weight gain, and no hypoglycaemia at 26 weeks — significantly more than active comparators including sitagliptin, exenatide, and insulin glargine.

Weight Management Research

While dulaglutide was developed primarily for glycaemic control, its weight management effects have attracted increasing research interest — particularly following the AWARD-11 evaluation of higher doses. For those comparing Trulicity weight loss outcomes with other GLP-1 receptor agonists, the evidence is meaningful but more modest than newer agents in the class.

Weight-related findings across the AWARD programme include:

AWARD-1: dulaglutide 1.5 mg produced weight reductions of approximately -1.30 kg from baseline at 26 weeks, with exenatide twice daily producing -1.07 kg.[1]
AWARD-4: dulaglutide 1.5 mg demonstrated a mean weight difference of -3.23 kg compared with insulin glargine at 52 weeks. Approximately 21.7% of patients achieved ≥3% weight loss versus 5.7% with glargine.[5]
AWARD-5: dulaglutide 1.5 mg produced -2.88 kg weight loss at 104 weeks versus -1.75 kg with sitagliptin (p < 0.001).[6]
AWARD-11: the higher 4.5 mg dose achieved -4.7 kg weight loss at 36 weeks versus -3.0 kg with 1.5 mg (p < 0.001), suggesting a dose–response relationship for Trulicity weight loss effects.[3]

Contextually, dulaglutide’s weight effects are moderate compared with semaglutide 2.4 mg (STEP programme: ~15% body weight reduction) and tirzepatide (SURMOUNT programme: up to ~22.5% reduction). This positions dulaglutide as a compound with meaningful metabolic weight benefits in the context of the Fat Loss & Recomp goal, but not as the primary choice when maximal weight reduction is the dominant research objective.

Cardiovascular Evidence

The REWIND (Researching Cardiovascular Events With a Weekly Incretin in Diabetes) trial is dulaglutide’s most significant contribution to the cardiovascular evidence base and stands as one of the most important GLP-1 receptor agonist outcomes trials conducted.

Key features of REWIND that distinguish it from other GLP-1 RA cardiovascular outcomes trials (CVOTs):

Broad population: unlike LEADER (liraglutide) and SUSTAIN-6 (semaglutide), which enrolled predominantly high-cardiovascular-risk patients, REWIND included participants with cardiovascular risk factors or established cardiovascular disease — a more representative population of typical patients with type 2 diabetes.
Lower baseline HbA1c: median baseline HbA1c of 7.2% (vs 8.7% in LEADER and 8.7% in SUSTAIN-6), demonstrating cardiovascular benefit even in well-controlled participants.
More women: 46.3% female participants, substantially more than other GLP-1 RA CVOTs.
Longest follow-up: median 5.4 years, the longest of any GLP-1 receptor agonist CVOT.

The primary results (Gerstein 2019): dulaglutide 1.5 mg reduced the primary composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death by 12% (hazard ratio 0.88, 95% CI 0.79–0.99, p = 0.026) compared with placebo in 9,901 participants.[2] A subsequent meta-analysis of all seven GLP-1 RA CVOTs (Kristensen 2019) confirmed a consistent class-wide 12% MACE reduction (HR 0.88, 95% CI 0.82–0.94, p < 0.0001), with dulaglutide’s REWIND contributing meaningfully to this pooled estimate.[9]

Renal & Organ-Protective Effects

An exploratory analysis of REWIND specifically examined dulaglutide’s renal outcomes over the 5.4-year median follow-up (Gerstein 2019). The composite renal endpoint — comprising new macroalbuminuria, sustained ≥30% decline in eGFR, or chronic renal replacement therapy — was reduced by 15% with dulaglutide versus placebo (HR 0.85, 95% CI 0.77–0.93, p = 0.0004).[8]

This renal signal was driven primarily by a reduction in new-onset macroalbuminuria, with less clear effects on hard renal endpoints (sustained eGFR decline and renal replacement therapy). While this represents a meaningful signal, it should be interpreted with caution as an exploratory analysis from a cardiovascular — not renal — outcomes trial.

Additionally, the dedicated AWARD-7 trial (Tuttle 2018) specifically evaluated dulaglutide in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (CKD stages 3–4). Over 52 weeks, dulaglutide maintained eGFR stability compared with insulin glargine, with both doses showing slower rates of eGFR decline and greater reductions in urinary albumin-to-creatinine ratio (UACR). This trial is particularly relevant because dulaglutide, unlike many antihyperglycaemic agents, is not cleared by the kidneys — potentially offering advantages in CKD populations.[10]

Side Effects & Safety Profile

The dulaglutide side effects profile is well-characterised across the AWARD programme and REWIND, involving more than 15,000 patient-years of exposure data. Trulicity side effects are consistent with the broader GLP-1 receptor agonist class.

Commonly reported adverse events include:

Gastrointestinal effects: nausea (the most common, reported in 12–17% of participants in AWARD trials), diarrhoea (8–16%), vomiting (5–14%), and constipation. These effects are typically dose-dependent, most pronounced during the initial weeks of treatment, and usually mild to moderate in severity. They are the most common reason for treatment discontinuation.[1][3][4]
Injection site reactions: generally mild and infrequent, reported in <5% of participants across trials.
Hypoglycaemia: low risk when used as monotherapy or with metformin, consistent with the glucose-dependent mechanism. Risk increases when combined with sulfonylureas or insulin.[1][5]

Important safety signals requiring monitoring:

Thyroid C-cell tumours (boxed warning): as with all GLP-1 receptor agonists, dulaglutide carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies. Clinical relevance to humans remains uncertain, but the compound is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pancreatitis: rare cases have been reported. Large-scale safety data from REWIND (5.4-year follow-up) did not demonstrate a statistically significant increase in pancreatitis incidence, though vigilance is warranted.[2]
Gallbladder events: consistent with other GLP-1 receptor agonists and weight loss interventions generally, cholelithiasis has been reported at modestly increased rates.

Half-Life & Pharmacokinetics

Dulaglutide’s pharmacokinetic profile is defined by its Fc fusion engineering. The approximate half-life of ~5 days (approximately 120 hours) supports once-weekly dosing, with peak plasma concentrations typically occurring 24–72 hours after subcutaneous injection.

Key pharmacokinetic properties:

Half-life: approximately 5 days (~120 hours), achieved through the IgG4 Fc fusion mechanism that prevents rapid renal clearance and engages FcRn-mediated recycling.
Steady-state: reached within 2–4 weeks of weekly dosing, with approximately 1.5-fold accumulation at steady state.
Renal clearance: minimal. Unlike many peptide therapies, dulaglutide is not predominantly cleared by the kidneys, making it suitable for investigation in CKD populations (as demonstrated in AWARD-7).[10]
Bioavailability: approximately 47–65% following subcutaneous injection at various anatomical sites (abdomen, thigh, upper arm), with no clinically significant differences between injection locations.

Compared with other GLP-1 receptor agonists: liraglutide has a half-life of approximately 13 hours (requiring daily dosing), while semaglutide has a half-life of approximately 7 days (also weekly dosing). Dulaglutide’s 5-day half-life sits between these, though all three support effective weekly or daily dosing regimens as designed.

FAQ

What is dulaglutide used for in research?